Implantable transvenous cardioverter-defibrillators in adults

Abstract

Ms. K, 59, has a history of type 2 diabetes, depression, heart failure (HF) with reduced ejection fraction (HFrEF), and renal insufficiency. Three months ago, she experienced a myocardial infarction (MI) that led to HF. Ms. K’s ejection fraction during her last hospitalization was 30%, and she is New York Heart Association (NYHA) functional class III. She was admitted for placement of an implantable cardioverter-defibrillator (ICD).